X
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    EU Approval for Koselugo

    AstraZeneca Secures EU Approval for Koselugo to Treat NF1 PN

    Cancer Research

    Guardant Health, Zephyr AI Collab to Advance Cancer Research

    CDMO market growth trends

    Biobeat Report: CDMO Growth in China and USA for 2026

    Ulcerative Colitis

    FDA Approves Omvoh by Eli Lilly for Ulcerative Colitis

    digital validation pharma

    Digital Validation and Compliance in Pharma

    green bioprocessing pharma

    Carbon-Neutral Bioprocessing in Pharmaceuticals

    precision fermentation biotech

    Precision Fermentation and the Future of Biomanufacturing

    cell therapy biotech

    Regenerative Medicine and Cell Therapy Innovations

    smart pharma labs

    Digital Transformation of Smart Pharma R&D Labs

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    EU Approval for Koselugo

    AstraZeneca Secures EU Approval for Koselugo to Treat NF1 PN

    Cancer Research

    Guardant Health, Zephyr AI Collab to Advance Cancer Research

    CDMO market growth trends

    Biobeat Report: CDMO Growth in China and USA for 2026

    Ulcerative Colitis

    FDA Approves Omvoh by Eli Lilly for Ulcerative Colitis

    digital validation pharma

    Digital Validation and Compliance in Pharma

    green bioprocessing pharma

    Carbon-Neutral Bioprocessing in Pharmaceuticals

    precision fermentation biotech

    Precision Fermentation and the Future of Biomanufacturing

    cell therapy biotech

    Regenerative Medicine and Cell Therapy Innovations

    smart pharma labs

    Digital Transformation of Smart Pharma R&D Labs

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Americas

FDA approves Jardiance tablets for type 2 diabetes

Yuvraj_pawp by Yuvraj_pawp
4th August 2014
in Americas, FDA Approvals, News

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

The US Food and Drug Administration (FDA) has approved Jardiance (empagliflozin) tablets, developed by Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company, as an addition to diet and exercise to improve glycemic control in adults with type II diabetes.

Jardiance is a once-daily, 10mg or 25mg tablet that was approved in the US based on data from a large clinical programme comprising at least ten multinational clinical trials and more than 13,000 adults with type II diabetes.

In Phase III clinical trials, patients demonstrated a significant reduction in hemoglobin A1C and fasting blood sugar after 24 weeks, using Jardiance as a standalone treatment or in combination with a range of background treatments, including metformin, sulfonylureas, insulin and pioglitazone.

Urinary tract infections and vaginal yeast infections were the most common adverse reactions associated with Jardiance in these studies.

Hypoglycemia was more commonly reported in patients treated with the combination of Jardiance and sulfonylurea or insulin.

“Jardiance is a new option that has been shown in clinical trials to reduce blood sugar levels.”

Boehringer metabolic-clinical development and medical affairs vice-president Dr Christophe Arbet-Engels said: “Jardiance is a new option that has been shown in clinical trials to reduce blood sugar levels.

“Although not approved for weight loss, modest weight loss was also observed in these clinical trials.”

Empagliflozin is a sodium glucose co-transporter 2 inhibitor that blocks the reabsorption of glucose by the kidney, increasing glucose excretion and lowering blood glucose levels.

Jardiance is not for people with type I diabetes or for people with diabetic ketoacidosis.

In January 2011, Boehringer Ingelheim and Lilly announced their alliance to develop compounds for several of the largest diabetes treatment classes. Jardiance is the third diabetes medicine they have developed as part of this alliance.

 

Tags: America
Previous Post

Rosetta Genomics Announces Agreement With Global Pharmaceutical Company to Advance Efforts in Alzheimer's Disease Diagnostics

Next Post

Pharma firms earn high margins; govt asked to cut MRP of drugs

Related Posts

EU Approval for Koselugo
Drug Development

AstraZeneca Secures EU Approval for Koselugo to Treat NF1 PN

31st October 2025
Cancer Research
Drug Development

Guardant Health, Zephyr AI Collab to Advance Cancer Research

30th October 2025
Ulcerative Colitis
Americas

FDA Approves Omvoh by Eli Lilly for Ulcerative Colitis

29th October 2025
Avidity Biosciences
Americas

Novartis to Acquire Avidity Biosciences in $12 Billion Deal

28th October 2025
manufacturing facility
Americas

AstraZeneca Unveils Expanded Manufacturing Facility in Texas

28th October 2025
GLP1 therapy
Americas

FDA Approves Novo Nordisk’s Rybelsus Oral GLP-1 Therapy

27th October 2025
Next Post

Alexion receives orphan drug designation for Soliris in Europe

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In